AFT Pharmaceuticals: FY23 Result — On Script
We liked what we saw in AFT Pharmaceuticals' (AFT) FY23 result: (1) ANZ revenue (AFT's core defensive growth driver) grew +24% versus FY22, (2)...
549 Views
AFT Pharmaceuticals (AFT): FY23 Result – First Impressions
AFT Pharmaceuticals (AFT) reported an operating FY23 result in-line with guidance and slightly ahead of our expectations with EBIT ex licensing...
488 Views
AFT Pharmaceuticals: FY23 Preview — Story Remains Intact
We expect AFT Pharmaceuticals' (AFT) underlying FY23 result to show strong growth, led by its Australia and New Zealand segments, when it reports...
309 Views
AFT Pharmaceuticals: Breaking the Pain Barrier
AFT Pharmaceuticals' (AFT) notification of US FDA approval for its rapid release tablet form of Maxigesic provides a material long-term opportunity.
327 Views
AFT Pharmaceuticals (AFT): Maxigesic Rapid US Tablet Approval
AFT Pharmaceuticals (AFT) has today announced US FDA approval of its rapid release tablet form of Maxigesic, which is step one in the process for...
393 Views